Hecla Mining Company Common Stock vs Personalis Inc. Common Stock — how do they compare? Hecla Mining Company Common Stock trades at $15.24 (market cap $10.87B), while Personalis Inc. Common Stock trades at $16.14 (market cap $1.69B). The key difference: Hecla Mining Company Common Stock is far larger — about 6.4× Personalis Inc. Common Stock's market cap, and Hecla Mining Company Common Stock pays a 0.09% dividend while Personalis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hecla Mining Company Common Stock for 3 Days and Personalis Inc. Common Stock for 0 Days on average.
| HL | PSNL | |
|---|---|---|
Market Cap | $10.87B | $1.69B |
Volume | 31,516,848 | 3,817,236 |
Sector | Basic Materials | Health |
52-Week High | $31.81 | $18.38 |
52-Week Low | $11.97 | $5.04 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $10.40B | $1.52B |
Dividend Yield | 0.09% | — |
Signals from Pluang's Aura AI — not financial advice
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →